This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: G71.2 | Special Copayment Reduction: V012 | Coverage period: 5 years |
| B. Synonyms | Multicore disease, minicore disease, congenital myopathy (general), fiber type disproportion (CFTD), congenital muscular dystrophy NOS, congenital muscular dystrophy with specific morphological abnormalities of muscle fibers |
| C. Adult onset | Likelihood of first onset in adulthood: low — most cases begin at birth to infancy; in some mild SELENON variants, diagnosis may be delayed until late childhood |
| 1. History | → Go to section | Classification developed in the 1960s–70s; SELENON identified in 2001, LAMA2 in 1994 |
| 2. Causes | → Go to section | Many genes, including SELENON, RYR1, TPM3, LAMA2, COL6A, POMT1 |
| 3. Genetics | → Go to section | Mainly AR; some AD (COL6A, etc.); very high genetic heterogeneity |
| 4. Epidemiology | → Go to section | Combined prevalence about 1–5/100,000; each subtype very rare |
| 5. Pathophysiology | → Go to section | Differs by subtype; abnormal muscle fiber structure and function, basement membrane defects |
| 6. Symptoms | → Go to section | Hypotonia at birth, respiratory failure, joint contractures common |
| 7. Signs | → Go to section | Rigid spine, respiratory failure, joint contractures, skin abnormalities (COL6A) |
| 8. Screening | → Go to section | CK, EMG, muscle MRI, brain MRI (LAMA2) |
| 9. Diagnosis | → Go to section | Muscle biopsy, immunohistochemistry, gene panel/WES |
| 10. Treatment | → Go to section | Supportive care; cyclosporine for COL6A in preclinical stage |
| 11. Prognosis | → Go to section | Varies greatly by subtype and gene |
| 12. Prevention | → Go to section | Genetic counseling, prenatal testing |
| 13. References | → Go to section | 10 key references |
The history of congenital myopathy (CM) and congenital muscular dystrophy (CMD) dates back to Shy and Magee's description of central core disease in 1956 and Ford's early record of congenital muscular dystrophy in 1961. However, molecular genetic definition of the distinct subtypes began in earnest only from the 1990s.
Multi-minicore disease (MmD) was named in 1971 when Engel and Gomez independently described a myopathy showing multiple small cores (minicores or multicores) within muscle fibers. Subsequently, in 2001 Moghadaszadeh et al. identified mutations in the SELENON gene (then SEPN1, selenoprotein N), and in the same year Ferreiro et al. showed that SELENON variants and rigid spine muscular dystrophy (RSMD1) are due to the same gene, making it clear that MmD and RSMD1 belong to a single clinical-genetic spectrum.
As major causative genes of congenital muscular dystrophy, laminin-α2 (LAMA2, merosin) was identified by Tomé et al. in 1994, and the COL6A genes (collagen type VI) were established as the cause of Ullrich CMD and Bethlem myopathy in the late 1990s to early 2000s. Brain-eye-muscle CMDs (POMT1, POMT2, FKTN, etc.) began to be classified in the 2000s as a series of dystroglycanopathies due to abnormal O-mannosyl protein glycosylation. Congenital fiber type disproportion (CFTD) was first proposed by Brooke in 1973, and variants in various genes including TPM3 were shown to be causes from the 2000s onward.
The subtypes in this category each have different molecular causes, and genetic heterogeneity is very high.
| Subtype | Main genes | Mode of inheritance | Key features |
|---|---|---|---|
| MmD/RSMD1 | SELENON | AR | Rigid spine, respiratory failure precede |
| MmD | RYR1 | AR | May be accompanied by external ophthalmoplegia |
| MDC1A | LAMA2 | AR | Merosin deficiency, cerebral white matter abnormalities |
| Ullrich CMD | COL6A1/A2/A3 | AR (some de novo) | Joint hyperlaxity + contractures, skin abnormalities |
| Bethlem myopathy | COL6A1/A2/A3 | AD | Mild, possible adult onset |
| Dystroglycanopathy | POMT1/POMT2/FKTN, etc. | AR | Accompanied by brain · eye abnormalities (Walker-Warburg, etc.) |
| CFTD | TPM3, ACTA1, etc. | AD/AR | Fiber type disproportion, nonspecific |
Because genetic heterogeneity in this category is extremely high, a congenital myopathy/muscular dystrophy panel or whole exome sequencing is more efficient than single-gene testing. Even without a family history, autosomal recessive forms are common, so parental carrier testing and sibling risk assessment are needed.
The individual subtypes in this category are each extremely rare. The prevalence of congenital muscular dystrophy overall is estimated at about 1–9/100,000. MDC1A (LAMA2 deficiency) is the most common form of CMD, accounting for about 30–40% of all CMD, with a prevalence of about 1–2/100,000. Ullrich CMD accounts for about 15–20% of CMD.
The prevalence of MmD/RSMD1 is rare, less than about 1/200,000. A founder effect for SELENON variants has been reported in the Mediterranean region and in Moroccan immigrant populations. Dystroglycanopathies are distributed worldwide, but individual subtypes are very rare at 1/1,000,000 or less.
In Korea, various causative genes have been identified since the introduction of whole exome sequencing, and LAMA2 and COL6A variants are reported relatively often.
The pathophysiology differs by subtype, but the common core is loss of function of proteins involved in maintaining muscle fiber structure, basement membrane stability, or muscle developmental signaling.
Selenoprotein N (SELENON) is a glycoprotein located in the endoplasmic reticulum lumen and is involved in regulation of sarcoplasmic reticulum calcium homeostasis and defense against oxidative stress. In SELENON deficiency, endoplasmic reticulum stress, oxidative damage, and abnormal RyR-related calcium signaling occur, forming multiple small cores (minicores) within muscle fibers. The rigid spine finding is due to fibrosis and fatty infiltration of the paraspinal muscles.
Laminin-α2 is a key component of the basement membrane and stabilizes the muscle cell basement membrane as the α2-β1-γ1 laminin complex. LAMA2 deficiency → basement membrane instability → repeated muscle fiber necrosis · regeneration → progressive fibrosis. Peripheral nerve myelination is also affected, so combined neuromuscular lesions are possible. White matter signal abnormalities are observed on brain MRI, but clinical cognitive impairment is mild in most cases.
Collagen type VI is a component of the extracellular matrix surrounding muscle cells and transmits muscle cell survival signals by interacting with integrins and laminins. COL6A deficiency causes loss of mitochondrial membrane potential, excessive apoptosis, and muscle fiber necrosis. Ullrich CMD (AR) is severe from birth, while Bethlem myopathy (AD) shows mild progression from childhood through adulthood.
Deficiency of O-mannosylation-related enzymes (POMT1, POMT2, FKTN, etc.) → abnormal glycosylation of α-dystroglycan → loss of laminin · agrin binding → basement membrane instability → combined involvement of muscle · brain · eye. Neuronal migration defect is characteristic, forming a spectrum from Walker-Warburg syndrome (most severe) to LGMD2I.
Symptoms common regardless of subtype are as follows.
| Test | Findings and significance |
|---|---|
| Serum CK | MmD (SELENON): normal to mildly elevated. MDC1A: moderately elevated (2–10×ULN). Dystroglycanopathies: may be severely elevated. |
| EMG | Myopathic findings. Nerve conduction abnormalities may be present in MDC1A (peripheral nerve involvement). |
| Muscle MRI | Subtype-specific characteristic patterns: SELENON selectively involves cervical and paraspinal muscles; MDC1A shows widespread muscle degeneration. |
| Brain MRI | MDC1A: T2 white matter signal abnormalities. Dystroglycanopathies: neuronal migration defect, hydrocephalus, cerebellar abnormalities. |
| Ophthalmologic examination | Retinal dysplasia and microphthalmia confirmed in dystroglycanopathies. |
| ECG · echocardiography | Check for associated cardiomyopathy, e.g., with FKTN variants. |
| Pulmonary function tests | FVC, MIP, MEP; monitoring for early respiratory muscle weakness essential in SELENON variants. |
A comprehensive congenital myopathy/muscular dystrophy panel (≥50 genes) or WES is more efficient than single-gene testing. Integrating pathological findings and clinical phenotype to narrow the range of candidate genes is important. RNA sequencing is useful for detecting splicing variants.
There is currently no curative treatment for the disorders in this category, and multidisciplinary supportive care according to subtype is the basis.
Prognosis differs greatly by subtype.